Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics announced the removal of a clinical hold by the FDA on its AlloCAR T clinical trials following an investigation. The investigation confirmed the chromosomal abnormality found in a patient was unrelated to Allogene's manufacturing process or TALEN gene editing. Clinical trials across the AlloCAR T platform are set to resume, with the pivotal Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma expected to start in mid-2022, pending FDA discussions. The company expresses gratitude for the collaboration with the FDA and clinical investigators.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that its President and CEO, David Chang, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 12:45 p.m. PT. This presentation focuses on the development of allogeneic CAR T therapies for cancer by Allogene, a pioneering biotechnology firm based in South San Francisco. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. For further details, visit www.allogene.com.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced a lease agreement to expand its headquarters in South San Francisco, effective April 1, 2022. The new facility will add 47,566 square feet of office and laboratory space, increasing total occupancy to over 100,000 square feet. This expansion supports Allogene's research capabilities and clinical development of AlloCAR T™ therapies aimed at treating hematologic cancers and solid tumors. The company has also developed a cutting-edge manufacturing facility in Newark, California.

Allogene Therapeutics (NASDAQ: ALLO) announced promising results from the Phase 1 UNIVERSAL trial of ALLO-715, the first allogeneic anti-BCMA CAR T therapy for multiple myeloma demonstrating substantial safety and efficacy. The trial achieved a 71% overall response rate (ORR), with 46% achieving a very good partial response (VGPR) or better. Notably, no cases of graft-versus-host disease were reported. The study enables rapid therapy initiation, with a median treatment start time of five days. ALLO-715 received RMAT designation from the FDA, reinforcing its potential in treating relapsed/refractory myeloma.

Allogene Therapeutics reported promising results from its Phase 1 trials (ALPHA and ALPHA2) of AlloCAR T therapy for treating large B-cell lymphoma and follicular lymphoma. The therapy exhibited a 44% complete response rate in large B-cell lymphoma patients, with no relapses observed in those achieving complete response at six months. The regimen was well tolerated, showing low adverse event rates. Allogene plans to initiate a pivotal Phase 2 trial in relapsed/refractory large B-cell lymphoma, contingent upon discussions with the FDA, aiming for accelerated patient treatment timelines.

Allogene Therapeutics (Nasdaq: ALLO) announced a conference call scheduled for December 13, 2021, at 1:30 PM PT/4:30 PM ET. The call will cover data from the ALPHA, ALPHA2, and UNIVERSAL Phase 1 trials concerning their AlloCAR T™ therapies for treating relapsed/refractory non-Hodgkin lymphoma and multiple myeloma. The live call can be accessed via phone or webcast, with a replay available for 30 days on their website. Allogene specializes in developing innovative, scalable cell therapies for cancer.

Allogene Therapeutics (Nasdaq: ALLO), a biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, announced its participation in five virtual investor conferences. These include Cowen's IO Next Summit on November 15, Stifel's Healthcare Conference on November 16, and others through December 6. Webcasts will be available on Allogene's website, providing investors with insights into the company's innovative therapies and future developments.

Allogene Therapeutics (ALLO) recently announced updates surrounding its AlloCAR T™ clinical trials, including presentations at the upcoming American Society of Hematology annual meeting.

The ALPHA2 trial showcased the benefits of consolidation dosing with ALLO-501A in relapsed/refractory large B-cell lymphoma. The company reported a third-quarter net loss of $78.2 million and ended the quarter with $862 million in cash and equivalents. Ongoing discussions with the FDA aim to resolve a clinical hold on its trials following a chromosomal abnormality report.

Allogene Therapeutics (ALLO) announced the selection of three abstracts for oral and poster presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 13, 2021. The presentations will showcase updated data from the ALPHA2 study of ALLO-501A in large B-cell lymphoma, the ALPHA study of ALLO-501 in non-Hodgkin lymphoma, and the UNIVERSAL study of ALLO-715 in multiple myeloma. These findings highlight the potential of AlloCAR T therapies in treating relapsed/refractory blood cancers, with encouraging efficacy and manageable safety profiles reported.